•FGFR inhibitor cancer drugs linked to dry eye, corneal damage•Eyebot partners with QUAY to install in-store vision kiosks•FDA clears ZEISS Clinic 360 ophthalmic analytics dashboard•Study finds sex differences in uveitis risk among GLP-1 users•EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial•FGFR inhibitor cancer drugs linked to dry eye, corneal damage•Eyebot partners with QUAY to install in-store vision kiosks•FDA clears ZEISS Clinic 360 ophthalmic analytics dashboard•Study finds sex differences in uveitis risk among GLP-1 users•EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial
HEADLINES
FEATURED
Federal agency added Class II classification last week after identifying the potential risk for sterility issues with the OTC product.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
